Convenia
Active substance
ATC code
Species
Dogs and cats.
Indications
For use only for the following infections which require prolonged treatment. The antimicrobial activity of the veterinary medicinal product following a single injection lasts for up to 14 days.
Dogs:
For the treatment of skin and soft tissue infections including pyoderma, wounds and abscesses associated with Staphylococcus pseudintermedius, β-haemolyticStreptococci, Escherichia coli and/or Pasteurella multocida.
For the treatment of urinary tract infections associated with Escherichia coli and/or Proteus spp.
As adjunctive treatment to mechanical or surgical periodontal therapy in the treatment of severe infections of the gingiva and periodontal tissues associated with Porphyromonas spp. and Prevotella spp. (see also section 3.5 ‘Special precautions for safe use in the target species’).
Cats:
For the treatment of skin and soft tissue abscesses and wounds associated with Pasteurella multocida, Fusobacterium spp., Bacteroides spp., Prevotella oralis, β-haemolytic Streptococci and/or Staphylococcus pseudintermedius.
For the treatment of urinary tract infections associated with Escherichia coli.
Dose to be administered and administration route
Subcutaneous use.
Skin and soft tissue infections in dogs:
A single subcutaneous injection of 8 mg cefovecin/kg body weight (1 ml of the veterinary medicinal product per 10 kg body weight). If required, treatment may be repeated at 14-day intervals up to a further three times. In accordance with good veterinary practice, treatment of pyoderma should be extended beyond complete resolution of clinical signs.
Severe infections of the gingival and periodontal tissues in dogs:
A single subcutaneous injection of 8 mg cefovecin/kg body weight (1 ml of the veterinary medicinal product per 10 kg body weight).
Skin and soft tissue abscesses and wounds in cats:
A single subcutaneous injection of 8 mg cefovecin/kg body weight (1 ml of the veterinary medicinal product per 10 kg body weight). If required, an additional dose may be administered 14 days after the first injection.
Urinary tract infections in dogs and cats:
A single subcutaneous injection of 8 mg cefovecin/kg body weight (1 ml of the veterinary medicinal product per 10 kg body weight).
To reconstitute, withdraw the required volume of the supplied solvent from its vial (for 23 ml vial containing 978,65 mg of lyophilised powder reconstitute using 10 ml of solvent, or for 5 ml vial containing 390,55 mg of lyophilised powder reconstitute using 4 ml of solvent) and add to the vial containing the lyophilised powder. Shake the vial until the powder is seen to have fully dissolved.
The reconstituted solution is clear and practically free from particles. It is light yellow to reddish brown in colour.
As with other cephalosporins, the colour of the reconstituted solution may darken. However, if stored as recommended, potency is not affected.
Dosing tableAnimal weight (dogs and cats) | Volume to be administered |
2.5 kg | 0.25 ml |
5 kg | 0.5 ml |
10 kg | 1 ml |
20 kg | 2 ml |
40 kg | 4 ml |
60 kg | 6 ml |
To ensure a correct dosage, body weight should be determined as accurately as possible.
Adverse reactions
Dogs and cats:
Very rare (<1 animal / 10,000 animals treated, including isolated reports): | Injection site reaction, Digestive tract disorder (e.g. diarrhoea, emesis, anorexia), Hypersensitivity reaction (e.g. anaphylaxis, circulatory shock, dyspnoea)1, Neurological signs (e.g. ataxia, convulsion, seizure) |
1Appropriate treatment should be administered without delay.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
